Figure 2 | Scientific Reports

Figure 2

From: 19F-perfluorocarbon-labeled human peripheral blood mononuclear cells can be detected in vivo using clinical MRI parameters in a therapeutic cell setting

Figure 2

The functionality of both APC and T cells is not affected as a result of 19F-PFC labeling. (a–c) PBMC from healthy volunteers were either labeled with 19F-PFC overnight (5 mg/mL) or remained unlabeled and then subjected to T cell positive selection removal. Remaining labeled and unlabeled APC were then employed in a MLR (a) by co-culturing with allogeneic CFSE+ T cells. Flow cytometry was used to assess T cell proliferation using CFSE dilution as a readout for both CD8+ (b) and CD4+ T cells (c). (d–f) Alternatively, T cell functionality was assessed using CFSE dilution for 19F-PFC-labeled and unlabeled T cells as a result of CD3 crosslinking (d) for both CD8+ (e) and CD4+ (F) T cells. No significant difference exists in either APC or T cell functionality as a results of 19F-PFC labeling (n = 3, mean ± SEM, p > 0.05).

Back to article page